



ASX release

8 March 2011

## **US\$0.6 million new pharmaceutical contract**

AtCor Medical (ASX: ACG), the developer and marketer of the SphygmoCor® system, which measures central blood pressures and arterial stiffness noninvasively, today announced that it has signed a new US\$0.6 million agreement to supply SphygmoCor systems and clinical trial support services to a major international pharmaceutical company.

Duncan Ross, CEO of AtCor Medical said, “AtCor has converted another contract due to the strength of both SphygmoCor technology and our clinical trial applications and data management services in pharmaceutical trials. We are especially pleased that the assessment of central pressures and arterial stiffness continues to grow beyond hypertension therapies, such as this study, and across disease states as drug companies endeavor to fully characterize the clinical benefits of new and existing drug therapies”. Mr Ross continued “over the past five years there has been mounting evidence of both positive and detrimental effects on central pressures and arterial stiffness in a number of drug classes which has captured the attention of both regulators and the pharmaceutical industry.”

Additional pharmaceutical contracts are being negotiated and are expected to close during the current fiscal year.

### **About AtCor Medical**

AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central blood pressure non-invasively. The company’s SphygmoCor® system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring. More than 2,100 SphygmoCor® systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company’s technology has been featured in hundreds of peer-reviewed studies published in leading medical journals. AtCor has operations in Australia, the United States, and Europe. For further information, please visit our web site at [www.atcormedical.com](http://www.atcormedical.com).

*For further information, please contact:*

Duncan Ross – AtCor Medical CEO  
+1 (630) 228 8873

Peter Manley – AtCor Medical CFO  
+61 (2) 9874 8761

*Media enquiries to:*

Ashley Rambukwella – Financial &  
Corporate Relations  
Ph: +61 (2) 8264 1004/ m. 0407 231 282 or  
[a.rambukwella@fcr.com.au](mailto:a.rambukwella@fcr.com.au)